Table 2.
Summary of resource utilization and costs in the Tourcoing AIDS Reference Center: inputs for the CEPAC model of HIV disease and treatment in France.
| Variable | Average monthly cost, 2010€ (SD)a | Time spent in stage (person-months) |
|---|---|---|
| Stage 1: No history of AIDS-defining event by CD4 count (cells/µl)b | ||
| >500 | 220 (240) | 290,226 |
| 351 – 500 | 290 (390) | 181,888 |
| 201 – 350 | 370 (590) | 51,898 |
| 101 – 200 | 810 (2,270) | 20,507 |
| 51 – 100 | 870 (930) | 5,240 |
| ≤50 | 1,200 (1,590) | 3,953 |
| Stage 2: Acute AIDS-defining diseasec | ||
| Pneumocystis jiroveci pneumonia | 11,700 (5,610) | 1,230 |
| Mycobacterium avium complex | 6,390 (2,900) | 160 |
| Toxoplasmic encephalitis | 9.420 (6,400) | 533 |
| Cytomegalovirus infection | 11,640 (3,780) | 359 |
| Candida esophagitis | 6,180 (5,070) | 2,297 |
| Other AIDS-defining event | 6,340 (6,890) | 8,963 |
| Stage 3: History of at least one AIDS-defining event by CD4 count (cells/µl)b | ||
| >500 | 270 (330) | 32,376 |
| 351 – 500 | 390 (850) | 29,649 |
| 201 – 350 | 760 (1,840) | 16,135 |
| 101 – 200 | 1,050 (2,230) | 9,828 |
| 51 – 100 | 1,070 (1,190) | 2,198 |
| ≤50 | 920 (580) | 2,200 |
| Stage 4: Month of deathc | ||
| No history of an AIDS-defining event | 7,400 (7,970) | 1,077 |
| ≤30 days after an AIDS-defining event | 14,070 (8,000) | 566 |
| >30 days after an AIDS-defining event | 11,750 (8,670) | 475 |
SD, standard deviation.
a
Stage-specific cost estimates excluded the costs of antiretroviral drugs and CD4 count, HIV RNA and genotype tests. These costs were added individually to the stage-specific costs to allow for variations in laboratory testing frequency, ART initiation criteria, and the cost of newly available antiretroviral drugs.
b
From the Tourcoing AIDS Reference Center, January 2004 – December 2005.
c
From the Tourcoing AIDS Reference Center, January 1998 – December 2005.